

SKYRIZI INFUSION REIMBURSEMENT OPTIONS AND FAX FORM

! This form details the **options for reimbursement claim submission** for eligible, commercially insured SKYRIZI patients with Crohn’s disease who are enrolled in Skyrizi Complete. Eligible, commercially insured patients may pay as little as \$5 per dose on their SKYRIZI prescription and can get reimbursed for SKYRIZI treatment-related costs such as intravenous (IV) administration, lab tests, and monitoring.*

Claim submission options and steps:

1. Obtain your patient’s Explanation of Benefits (EOB) and ensure it contains the following information in order for the claim to be processed successfully: **a) Dates of Service; b) Product/Procedure Codes; c) Units Billed**

2. Use any of the following options to submit a claim:

FAX

Only if the EOB is missing any of the required information in step 1, **fill out the form below and fax it with the EOB to IQVIA at 631.822.2893**

OR

ONLINE PORTALS

Follow the steps to input/upload information at either portal:

- Complete Pro: <https://completepro.com/>
- IQVIA Reimbursement Portal: <https://completebuyandbill.opushealth.com/>

OR

ELECTRONIC

The ANSI EDI process can be used to submit the claim (using IQVIA Vendor ID: 15060). Contact a Field Access Specialist for assistance

3. Once the claim is approved, **funds will be loaded to the patient’s Skyrizi Complete Savings Card**, which the patient can use to pay their copay

FOR FAX OPTION ONLY (631.822.2893)

Additional Reimbursement Details, if Needed	
Patient information	
First name: _____	Last name: _____
Address: _____	
Sex: M <input type="checkbox"/> F <input type="checkbox"/>	Date of birth: ____ / ____ / ____
Phone: _____	
Skyrizi Complete Savings Card ID (if known): _____	Group number: _____
Administering provider name: _____	NPI #: _____
Administering site of care: _____	NPI #: _____

IMPORTANT INFORMATION: The categories of personal information collected in this form include patient demographic and prescribing info, and administering provider name, NPI and address. The personal information collected will be used for reimbursement and claims validation and to perform research and analytics on a de-identified (for patients only) basis. For more information about the categories of personal information collected by AbbVie and the purposes for which AbbVie uses personal information, visit <https://privacy.abbvie>

		Date(s) of Service (MM/DD/YY):		
Drug Select only one option per Date of Service	SKYRIZI - J2327 (Injection, risankizumab-rzaa, Intravenous, 1 mg)			
	SKYRIZI - J3590; provide NDC:			
	Check box if J-code not applicable (SP/free goods)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
		Check box for relevant Date of Service		
Administration support Enter CPT code(s) used		<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
		<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
		<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Lab support Enter CPT code(s) used		<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
		<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
		<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
		<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

For support in person or over the phone, call a Field Access Specialist at 1.877.COMPLETE (1.877.266.7538), or contact IQVIA Customer Support about the claim at 1.800.471.0186 (option 5)

ANSI=American National Standards Institute; CPT=Current Procedural Terminology; EDI=Electronic Data Interchange; NDC=national drug code; NPI=national provider identifier; SP=specialty pharmacy.

*Terms and Conditions apply. See page 2 for details.

INDICATION¹

SKYRIZI is indicated for the treatment of moderately to severely active Crohn’s disease in adults.

SAFETY CONSIDERATIONS¹

SKYRIZI is contraindicated in patients with a history of serious hypersensitivity reaction to risankizumab-rzaa or any of its excipients. Serious hypersensitivity reactions, including anaphylaxis, have been reported with use of SKYRIZI. If a serious hypersensitivity reaction occurs, discontinue SKYRIZI and initiate appropriate therapy immediately. SKYRIZI may increase the risk of infection. Instruct patients to report signs or symptoms of clinically important infection during treatment. Should such an infection occur, discontinue SKYRIZI until infection resolves. Evaluate patients for tuberculosis infection prior to initiating treatment with SKYRIZI. Drug-induced liver injury was reported in a patient with Crohn’s disease during induction dosing of SKYRIZI. For the treatment of Crohn’s disease, evaluate liver enzymes and bilirubin at baseline and during induction (12 weeks). Interrupt treatment with SKYRIZI if drug-induced liver injury is suspected, until this diagnosis is excluded. Avoid use of live vaccines in SKYRIZI patients.

Please see additional Important Safety Information on page 2. Please click here for full [Prescribing Information](#).



INDICATION AND IMPORTANT SAFETY INFORMATION FOR SKYRIZI® (risankizumab-rzaa)

INDICATION¹

SKYRIZI is indicated for the treatment of moderately to severely active Crohn's disease in adults.

IMPORTANT SAFETY INFORMATION¹

Hypersensitivity Reactions

SKYRIZI® (risankizumab-rzaa) is contraindicated in patients with a history of serious hypersensitivity reaction to risankizumab-rzaa or any of the excipients. Serious hypersensitivity reactions, including anaphylaxis, have been reported with the use of SKYRIZI. If a serious hypersensitivity reaction occurs, discontinue SKYRIZI and initiate appropriate therapy immediately.

Infection

SKYRIZI may increase the risk of infection. Do not initiate treatment with SKYRIZI in patients with a clinically important active infection until it resolves or is adequately treated.

In patients with a chronic infection or a history of recurrent infection, consider the risks and benefits prior to prescribing SKYRIZI. Instruct patients to seek medical advice if signs or symptoms of clinically important infection occur. If a patient develops such an infection or is not responding to standard therapy, closely monitor and discontinue SKYRIZI until the infection resolves.

Tuberculosis (TB)

Prior to initiating treatment with SKYRIZI, evaluate for TB infection and consider treatment in patients with latent or active TB for whom an adequate course of treatment cannot be confirmed. Monitor patients for signs and symptoms of active TB during and after SKYRIZI treatment. Do not administer SKYRIZI to patients with active TB.

Hepatotoxicity in Treatment of Crohn's Disease

Drug-induced liver injury was reported in a patient with Crohn's disease who was hospitalized for a rash during induction dosing of SKYRIZI. For the treatment of Crohn's disease, evaluate liver enzymes and bilirubin at baseline and during induction (12 weeks); monitor thereafter according to routine patient management. Consider an alternate treatment for patients with evidence of liver cirrhosis. Interrupt treatment if drug-induced liver injury is suspected, until this diagnosis is excluded. Instruct your patient to seek immediate medical attention if they experience symptoms suggestive of hepatic dysfunction.

Administration of Vaccines

Avoid use of live vaccines in patients treated with SKYRIZI. Medications that interact with the immune system may increase the risk of infection following administration of live vaccines. Prior to initiating SKYRIZI, complete all age appropriate vaccinations according to current immunization guidelines.

Adverse Reactions

Most common (>3%) adverse reactions associated with SKYRIZI in Crohn's disease are upper respiratory infections, headache, and arthralgia in induction and arthralgia, abdominal pain, injection site reactions, anemia, pyrexia, back pain, arthropathy, and urinary tract infection in maintenance.

Lipid Elevations: Increases from baseline and increases relative to placebo were observed at Week 4 and remained stable to Week 12 in patients treated with SKYRIZI in Crohn's disease.

Dosage Forms and Strengths: SKYRIZI is available in a 600 mg/10 mL single-dose vial for intravenous infusion and a 180 mg/1.2 mL or 360 mg/2.4 mL single-dose prefilled cartridge with on-body injector.

Savings Card Co-pay Program Terms and Conditions

*Eligibility: Available to patients with commercial insurance coverage for SKYRIZI® (risankizumab-rzaa) who meet eligibility criteria. This co-pay assistance program is not available to patients receiving prescription reimbursement under any federal, state, or government-funded insurance programs (for example, Medicare [including Part D], Medicare Advantage, Medigap, Medicaid, TRICARE, Department of Defense, or Veterans Affairs programs) or where prohibited by law. Offer subject to change or termination without notice. Restrictions, including monthly maximums, may apply. This is not health insurance. **For full Terms and Conditions for SKYRIZI Crohn's Disease patients, visit [SKYRIZICDSavingsCard.com](https://www.abbvie.com/skyrizi-crohn-s-disease-patients/skyrizi-cdsavingscard) or call 1.866.SKYRIZI for additional information.** To learn about AbbVie's privacy practices and your privacy choices, visit <https://privacy.abbvie.com>

Reference: 1. SKYRIZI [package insert]. North Chicago, IL: AbbVie Inc.

Please click here for full [Prescribing Information](#).

abbvie

© 2023 AbbVie. All rights reserved.
SKYRIZI® and its design are registered trademarks of AbbVie Biotechnology Ltd.

US-SKZG-230090 March 2023


Skyrizi[®]
risankizumab-rzaa